Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3

• 收藏
• 分享

专利权人:

F. HOFFMANN-LA ROCHE AG;GENENTECH, INC.; INC.;GENENTECH

发明人:

AMLER LUKAS C.,BIRKNER MERRILL,LIN CHIN-YU,MOECKS JOACHIM,STRAUSS ANDREAS,AMLER Lukas C.,BIRKNER Merrill,LIN Chin-Yu,MOECKS Joachim,STRAUSS Andreas

申请号：

SI200831228

公开号：

SI2132573T1

申请日:

2008.02.29

申请国别(地区):

SI

年份:

2014

代理人:

摘要：

The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/